Philips delivers strong order intake, comparable sales growth and margin expansion in Q1; 2026 outlook reiterated
Royal Philips reported a 6% growth in comparable order intake and a 4% increase in comparable sales in Q1 2026, with adjusted EBITA margin expanding 40 basis points to 9.0%. The company reiterated its 2026 outlook and highlighted its AI-powered innovations, including SmartHeart and DeviceGuide.
Royal Philips reported strong Q1 2026 results, with 6% comparable order intake growth and 4% comparable sales growth. Sales grew across segments, led by North America and Europe. The company's adjusted EBITA margin increased 40 basis points to 9.0%, driven by higher sales and productivity. Philips highlighted its AI-powered innovations, including SmartHeart, which automates cardiac MR imaging planning, and DeviceGuide, which provides real-time guidance during complex cardiac procedures. The company reiterated its 2026 outlook and remains the number one MedTech patent applicant in Europe.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.